Commerzbank set a €111.00 ($137.04) target price on Bayer (FRA:BAYN) in a report published on Friday, March 23rd. The firm currently has a buy rating on the healthcare company’s stock.
A number of other analysts also recently weighed in on the company. Barclays set a €100.00 ($123.46) target price on Bayer and gave the stock a sell rating in a research report on Tuesday, December 12th. UBS set a €125.00 ($154.32) target price on Bayer and gave the stock a buy rating in a research report on Thursday, December 7th. Goldman Sachs set a €125.00 ($154.32) target price on Bayer and gave the stock a buy rating in a research report on Tuesday, January 23rd. JPMorgan Chase set a €128.00 ($158.02) target price on Bayer and gave the stock a buy rating in a research report on Friday, December 29th. Finally, Citigroup restated a buy rating on shares of Bayer in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company. Bayer presently has an average rating of Buy and an average target price of €118.00 ($145.68).
Shares of BAYN traded up €2.70 ($3.33) during trading hours on Friday, reaching €100.68 ($124.30). 4,186,245 shares of the company’s stock traded hands. Bayer has a 12 month low of €91.58 ($113.06) and a 12 month high of €123.82 ($152.86).
COPYRIGHT VIOLATION NOTICE: “Bayer (FRA:BAYN) PT Set at €111.00 by Commerzbank” was originally reported by Macon Daily and is the property of of Macon Daily. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://macondaily.com/2018/04/17/commerzbank-analysts-give-bayer-bayn-a-111-00-price-target-updated-updated-updated.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.